MPO and chronic kidney disease: In another study, subjects with CKD were randomized for 8 weeks to receive either 4 g/day EΩ3FA (a combination of EPA and DHA), CoQ10, or a placebo of olive oil [36] to determine the effects on LTB4 and LTB5; other chemotactic agents produced by neutrophils such as myeloperoxidase; specialized pro-resolving mediators, such as 18-hydroxyeicosapentaenoic acid (HEPE) and 14-hydroxydocosahexaenoic acid (HDHA); and metabolites of EPA and DHA, such as resolvin (Rv)E2, RvE3, and RvD5.